JP2017510559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510559A5 JP2017510559A5 JP2016553491A JP2016553491A JP2017510559A5 JP 2017510559 A5 JP2017510559 A5 JP 2017510559A5 JP 2016553491 A JP2016553491 A JP 2016553491A JP 2016553491 A JP2016553491 A JP 2016553491A JP 2017510559 A5 JP2017510559 A5 JP 2017510559A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- egfrviii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950963P | 2014-03-11 | 2014-03-11 | |
| US61/950,963 | 2014-03-11 | ||
| PCT/US2015/019722 WO2015138460A1 (en) | 2014-03-11 | 2015-03-10 | Anti-egfrviii antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510559A JP2017510559A (ja) | 2017-04-13 |
| JP2017510559A5 true JP2017510559A5 (enExample) | 2018-04-19 |
| JP6632984B2 JP6632984B2 (ja) | 2020-01-22 |
Family
ID=52875228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553491A Active JP6632984B2 (ja) | 2014-03-11 | 2015-03-10 | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9475875B2 (enExample) |
| EP (1) | EP3126388B1 (enExample) |
| JP (1) | JP6632984B2 (enExample) |
| KR (1) | KR102399005B1 (enExample) |
| CN (1) | CN106459199B (enExample) |
| AU (1) | AU2015229591B2 (enExample) |
| BR (1) | BR112016020752B1 (enExample) |
| CA (1) | CA2940685C (enExample) |
| CL (1) | CL2016002252A1 (enExample) |
| CY (1) | CY1121870T1 (enExample) |
| DK (1) | DK3126388T3 (enExample) |
| EA (1) | EA035809B1 (enExample) |
| ES (1) | ES2736126T3 (enExample) |
| HR (1) | HRP20191335T1 (enExample) |
| HU (1) | HUE045307T2 (enExample) |
| IL (1) | IL247407B (enExample) |
| LT (1) | LT3126388T (enExample) |
| MA (1) | MA39313B1 (enExample) |
| ME (1) | ME03525B (enExample) |
| MX (1) | MX373280B (enExample) |
| MY (1) | MY178160A (enExample) |
| NZ (1) | NZ724229A (enExample) |
| PH (1) | PH12016501680B1 (enExample) |
| PL (1) | PL3126388T3 (enExample) |
| PT (1) | PT3126388T (enExample) |
| RS (1) | RS59077B1 (enExample) |
| SG (1) | SG11201606979TA (enExample) |
| SI (1) | SI3126388T1 (enExample) |
| SM (1) | SMT201900439T1 (enExample) |
| WO (1) | WO2015138460A1 (enExample) |
| ZA (1) | ZA201605894B (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| TWI899515B (zh) | 2015-08-04 | 2025-10-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| KR20250157457A (ko) * | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| WO2018091724A1 (en) * | 2016-11-21 | 2018-05-24 | Cureab Gmbh | Anti-gp73 antibodies and immunoconjugates |
| AU2018219909B2 (en) * | 2017-02-10 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
| CN114075269A (zh) | 2017-07-06 | 2022-02-22 | 菲仕兰坎皮纳荷兰私人有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| KR102119783B1 (ko) * | 2017-08-14 | 2020-06-08 | 사회복지법인 삼성생명공익재단 | 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편 |
| CN109912715A (zh) * | 2017-12-13 | 2019-06-21 | 凯惠科技发展(上海)有限公司 | 一种EGFRvIII抗体及其偶联物、制备方法和应用 |
| CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| KR20200115485A (ko) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| US12460270B2 (en) | 2018-02-28 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| BR112020015291B1 (pt) | 2018-03-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc | Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| IL284471B2 (en) | 2019-01-16 | 2025-01-01 | Regeneron Pharma | Methods for identifying free thiols in proteins |
| KR20210148228A (ko) | 2019-03-27 | 2021-12-07 | 내셔날 리서치 카운실 오브 캐나다 | 항-EGFRvIII 항체 및 그의 항원-결합 단편 |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| AU2020299382A1 (en) * | 2019-07-02 | 2022-01-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind EGFRvIII and their use |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| MX2022006236A (es) | 2019-11-25 | 2022-06-22 | Regeneron Pharma | Formulaciones de liberacion sostenida con emulsiones no acuosas. |
| KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| AU2021261681A1 (en) * | 2020-04-24 | 2022-12-08 | Merus B.V. | Treatment of cancers with an antibody that binds LGR5 and EGFR |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
| WO2022177676A1 (en) * | 2021-02-16 | 2022-08-25 | City Of Hope | Anti-domain iv egfr antibodies and uses thereof |
| CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
| US20220309215A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3212850A1 (en) * | 2021-06-22 | 2022-12-29 | Frank DELFINO | Anti-egfrviii antibody drug conjugates and uses thereof |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| JP2024539550A (ja) * | 2021-09-29 | 2024-10-29 | ナショナル リサーチ カウンシル オブ カナダ | ヒト化抗ｅｇｆｒｖｉｉｉ抗体及びその抗原結合断片 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| CN118076894A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH建模和控制的系统及方法 |
| KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
| CA3245647A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS |
| KR20250011926A (ko) * | 2022-05-18 | 2025-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도 |
| TW202435942A (zh) | 2022-12-16 | 2024-09-16 | 美商里珍納龍藥品有限公司 | 評估層析管柱完整性的方法及系統 |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445126A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 基於質譜法之體內共表現抗體之表徵 |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| AU2024305352A1 (en) | 2023-06-12 | 2025-12-04 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| WO2025014896A1 (en) * | 2023-07-07 | 2025-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Humanized 40h3 antibody |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025058A1 (en) | 2024-07-25 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Aav viral particles retargeted to egfr-expressing cancer cells |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| AUPP380498A0 (en) | 1998-05-29 | 1998-06-25 | Biomolecular Research Institute Limited | Egf receptor agonists and antagonists |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| DE60234094D1 (de) | 2001-05-11 | 2009-12-03 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
| JP2005508887A (ja) | 2001-08-03 | 2005-04-07 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法 |
| CA2530172A1 (en) * | 2003-06-27 | 2005-02-10 | Abgenix, Inc. | Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US20110142822A1 (en) * | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
| US20090269343A1 (en) * | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| CN102083461B (zh) | 2008-04-30 | 2014-09-17 | 伊缪诺金公司 | 有效的偶联物和亲水性连接体 |
| ES2536882T3 (es) | 2008-07-21 | 2015-05-29 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| BRPI1010035A2 (pt) | 2009-06-02 | 2015-08-25 | Regeneron Pharma | Células deficientes em fucosilação |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2464654B1 (en) | 2009-08-10 | 2014-10-08 | UCL Business PLC | Thiol protecting group |
| WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2012005982A2 (en) | 2010-07-06 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Reporter for rna polymerase ii termination |
| ME03353B (me) * | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| EP2714685B1 (en) | 2011-05-27 | 2016-10-19 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9526798B2 (en) | 2011-10-14 | 2016-12-27 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751076B1 (en) | 2011-10-14 | 2018-04-25 | MedImmune Limited | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| MX358757B (es) | 2011-10-14 | 2018-09-03 | Seattle Genetics Inc | Pirrolobenzodiazepinas y conjugados dirigidos. |
| BR112014008888A2 (pt) | 2011-10-14 | 2017-04-18 | Seattle Genetics Inc | pirrolobenzodiazepinas |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| EA201490974A1 (ru) | 2011-11-16 | 2014-09-30 | Эмджен Инк. | СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА |
| MX2014006739A (es) | 2011-12-05 | 2015-06-05 | Igenica Biotherapeutics Inc | Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos. |
| AU2014233385C1 (en) | 2013-03-15 | 2019-09-19 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| SI3030581T1 (sl) | 2013-08-07 | 2021-07-30 | Affimed Gmbh | Mesta za vezavo na protitelo, ki so specifična za EGFRVIII |
| RS59077B1 (sr) | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
-
2015
- 2015-03-10 RS RS20191002A patent/RS59077B1/sr unknown
- 2015-03-10 SG SG11201606979TA patent/SG11201606979TA/en unknown
- 2015-03-10 NZ NZ724229A patent/NZ724229A/en unknown
- 2015-03-10 CA CA2940685A patent/CA2940685C/en active Active
- 2015-03-10 LT LTEP15712472.8T patent/LT3126388T/lt unknown
- 2015-03-10 WO PCT/US2015/019722 patent/WO2015138460A1/en not_active Ceased
- 2015-03-10 EP EP15712472.8A patent/EP3126388B1/en active Active
- 2015-03-10 US US14/643,886 patent/US9475875B2/en active Active
- 2015-03-10 DK DK15712472.8T patent/DK3126388T3/da active
- 2015-03-10 PT PT15712472T patent/PT3126388T/pt unknown
- 2015-03-10 HR HRP20191335TT patent/HRP20191335T1/hr unknown
- 2015-03-10 MY MYPI2016703057A patent/MY178160A/en unknown
- 2015-03-10 PL PL15712472T patent/PL3126388T3/pl unknown
- 2015-03-10 MA MA39313A patent/MA39313B1/fr unknown
- 2015-03-10 SI SI201530830T patent/SI3126388T1/sl unknown
- 2015-03-10 JP JP2016553491A patent/JP6632984B2/ja active Active
- 2015-03-10 ME MEP-2019-202A patent/ME03525B/me unknown
- 2015-03-10 EA EA201691824A patent/EA035809B1/ru unknown
- 2015-03-10 KR KR1020167025833A patent/KR102399005B1/ko active Active
- 2015-03-10 AU AU2015229591A patent/AU2015229591B2/en active Active
- 2015-03-10 CN CN201580024031.3A patent/CN106459199B/zh active Active
- 2015-03-10 ES ES15712472T patent/ES2736126T3/es active Active
- 2015-03-10 SM SM20190439T patent/SMT201900439T1/it unknown
- 2015-03-10 BR BR112016020752-1A patent/BR112016020752B1/pt active IP Right Grant
- 2015-03-10 MX MX2016011619A patent/MX373280B/es active IP Right Grant
- 2015-03-10 HU HUE15712472A patent/HUE045307T2/hu unknown
-
2016
- 2016-06-01 US US15/170,628 patent/US10047160B2/en active Active
- 2016-08-21 IL IL247407A patent/IL247407B/en active IP Right Grant
- 2016-08-23 PH PH12016501680A patent/PH12016501680B1/en unknown
- 2016-08-24 ZA ZA2016/05894A patent/ZA201605894B/en unknown
- 2016-09-06 CL CL2016002252A patent/CL2016002252A1/es unknown
-
2018
- 2018-07-12 US US16/033,477 patent/US10738124B2/en active Active
-
2019
- 2019-08-08 CY CY20191100847T patent/CY1121870T1/el unknown
-
2020
- 2020-07-01 US US16/918,656 patent/US11608380B2/en active Active